This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Alkermes (ALKS) Recently Broke Out Above the 50-Day Moving Average
by Zacks Equity Research
Good things could be on the horizon when a stock surpasses the 50-Day simple moving average. How should investors react?
Here's Why Alkermes (ALKS) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Acadia (ACAD) Down 0.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Alkermes (ALKS) Grants Teva License to Market Generic Drug
by Zacks Equity Research
Alkermes (ALKS) grants Teva an exclusive license to market a generic version of Vivitrol in the United States, thereby resolving patent litigation. The stock of the company rises 7%.
Why Is Alkermes (ALKS) Down 9% Since Last Earnings Report?
by Zacks Equity Research
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Viatris (VTRS) Q2 Earnings Beat, Generics Business Grows
by Zacks Equity Research
Viatris (VTRS) second-quarter earnings and sales beat estimates. The company reiterates its annual guidance.
Bausch Health's (BHC) Q2 Earnings & Sales Beat, '23 View Raised
by Zacks Equity Research
Bausch's (BHC) second-quarter earnings and sales surpass estimates. The company increases its revenue guidance for 2023.
Gilead's (GILD) Q2 Earnings Miss, Revenues Beat on Oncology
by Zacks Equity Research
Gilead's (GILD) Q2 earnings miss on litigation charges while revenues beat on strong oncology and HIV franchise.
Puma Biotech (PBYI) Q2 Earnings Beat, Nerlynx Sales Outperform
by Zacks Equity Research
Puma Biotechnology (PBYI) beats second-quarter earnings and sales estimates. Stock rises in after-hours.
Exelixis (EXEL) Q2 Earnings Top, Cabometyx Drives Growth
by Zacks Equity Research
Exelixis (EXEL) beats second-quarter 2023 earnings and sales estimates as Cabometyx drives growth in approved indications.
Intercept (ICPT) Q2 Earnings Top Estimates, Revenues Up Y/Y
by Zacks Equity Research
Intercept (ICPT) reports a lower net loss and beats on revenues in the second quarter. The company also updates its guidance for its lead drug, Ocaliva.
BioMarin (BMRN) Q2 Earnings & Sales Top, Voxzogo Drives Sales
by Zacks Equity Research
BioMarin (BMRN) beats on earnings and sales estimates in the second quarter on the back of robust demand for Voxzogo.
Bristol-Myers (BMY) Q2 Earnings, Sales Miss, '23 View Lowered
by Zacks Equity Research
Bristol-Myers' (BMY) second-quarter 2023 earnings and sales miss estimates due to generic erosion for the oncology drug Revlimid. The company also cuts its forecast for 2023.
Alkermes (ALKS) Q2 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Alkermes (ALKS) reports encouraging second-quarter results, wherein both earnings and revenues beat estimates. This is due to strong growth in commercial execution of its proprietary products, Lybalvi and Vivitrol.
GSK Beats on Q2 Earnings & Sales, Raises 2023 Guidance
by Zacks Equity Research
GSK's revenues benefit from strong growth across all segments, especially HIV and vaccine. GSK raises guidance for earnings and sales. Shares rise in pre-market trading post the announcement.
Compared to Estimates, Alkermes (ALKS) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Alkermes (ALKS) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Alkermes (ALKS) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Alkermes (ALKS) delivered earnings and revenue surprises of 14.58% and 7.83%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Biogen (BIIB) Beats on Q2 Earnings & Sales, Announces Job Cuts
by Zacks Equity Research
Biogen (BIIB) beats second-quarter estimates for earnings and sales. It maintains 2023 guidance. Stock up in pre-market.
Philips (PHG) Q2 Earnings Beat Estimates, Revenue Rise Y/Y
by Zacks Equity Research
Philips' (PHG) second-quarter results benefit from robust performances by the Diagnosis & Treatment and the Connected Care businesses.
Gilead (GILD) Ends Myelodysplastic Syndromes Study on Magrolimab
by Zacks Equity Research
Gilead Sciences, Inc. (GILD) discontinues phase III ENHANCE study, evaluating the potential of magrolimab as a treatment for higher-risk myelodysplastic syndromes, due to futility based on a planned analysis.
Vir Biotechnology (VIR) Down on Influenza Study Failure
by Zacks Equity Research
Vir Biotechnology (VIR) crashes after the phase II study evaluating VIR-2482 for preventing symptomatic influenza A illness fails to meet goals.
Alkermes (ALKS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Higher sales of Alkermes' (ALKS) key drugs like Vivitrol, Aristada and Lybalvi are likely to have driven second-quarter sales.
J&J (JNJ) Q2 Earnings & Sales Top, '23 View Upped, Stock Jumps
by Zacks Equity Research
J&J (JNJ) beats estimates for second-quarter earnings and sales. It raises full-year sales and earnings guidance.
Will Alnylam Pharmaceuticals (ALNY) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Recursion (RXRX) Stock Surges 191% in 3 Months: Here's Why
by Zacks Equity Research
Recursion's (RXRX) shares rallied almost 191% over the past three months, owing to artificial intelligence-driven acquisitions and strategic collaborations to advance drug development.